Cristina Vazquez Guillamet

Medicine & Life Sciences

1. Acinetobacter 34%
2. Anti-Bacterial Agents 83%
3. Antimicrobial Stewardship 27%
4. Artificial Respiration 37%
5. B7-H1 Antigen 28%
6. Bacteremia 27%
7. Bronchoalveolar Lavage 19%
8. Candidemia 24%
9. Cefepime 26%
10. Clinical Decision Rules 26%
11. Cohort Studies 30%
12. Confidence Intervals 21%
13. Coronavirus 26%
14. Critical Care 22%
15. Critical Illness 81%
16. Decision Making 29%
17. Epidemiology 24%
18. Gram-Negative Bacteria 34%
19. Gram-Positive Bacteria 23%
20. Healthcare-Associated Pneumonia 29%
21. Heart 16%
22. Hospital Mortality 22%
23. Hospital Rapid Response Team 28%
24. Human Influenza 16%
25. Immunocompromised Host 21%
26. Infections 87%
27. Intensive Care Units 59%
28. Lung 58%
29. Meropenem 24%
30. Methicillin-Resistant Staphylococcus aureus 58%
31. Microbial Drug Resistance 29%
32. Mortality 53%
33. Multiple Drug Resistance 20%
34. Numbers Needed To Treat 22%
35. Odds Ratio 22%
36. Pneumonia 32%
37. Pseudomonas 22%
38. Retrospective Studies 17%
39. Sepsis 63%
40. Septic Shock 100%
41. Skilled Nursing Facilities 25%
42. Smoke 17%
43. Soft Tissue Infections 24%
44. Tazobactam Drug Combination Piperacillin 23%
45. Terminal Care 23%
46. Therapeutics 27%
47. Tobacco Products 17%
48. Transplant Recipients 56%
49. Vancomycin-Resistant Enterococci 17%
50. Ventilator-Associated Pneumonia 69%